RxDoctor Payments Data

Pankaj Shukla, MD

Internal Medicine · Bakersfield, CANPI 1114937190

Payments from drug & device makers

$6,460in general payments, 2019–2025

Across 419 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$904
  • Amgen$819
  • Nestle Healthcare Nutrition Inc.$300
  • Amarin Pharma, Inc.$289
  • Sunovion Pharmaceuticals Inc.$246
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,31198%
  • Education$901%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,460 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,028,145
Medicare patients
729
Services billed
29,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate618$504,039
OzempicSemaglutide478$438,213
FarxigaDapagliflozin Propanediol413$361,545
JardianceEmpagliflozin422$353,871
MounjaroTirzepatide270$271,820
LinzessLinaclotide277$205,570
EliquisApixaban162$151,635
TrulicityDulaglutide139$133,239
EntrestoSacubitril/Valsartan136$122,244
ProliaDenosumab57$95,067
ZenpepLipase/Protease/Amylase54$75,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$73,999
MyrbetriqMirabegron107$66,978
XareltoRivaroxaban73$63,460
TradjentaLinagliptin51$44,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$201$529,269647 claims
Novo NordiskOzempic, Rybelsus$1,029$477,492506 claims
Lilly USA, LLCMounjaro, Trulicity$138$405,059409 claims
Boehringer IngelheimJardiance, Tradjenta$198$398,006473 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$904$388,377461 claims
AbbVieLinzess, Namzaric, Creon$202$234,951316 claims
PfizerEliquis$96$151,635162 claims
NovartisEntresto$235$122,244136 claims
GSKTrelegy Ellipta, Breo Ellipta$196$97,971182 claims
AmgenProlia$819$95,06757 claims
Johnson & JohnsonXarelto$52$63,46073 claims
Sumitomo Pharma America, Inc.Gemtesa$44$20,90022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →